Menu
Read all about what we’ve been up to in our latest news and recent publications.
The Puget Sound Business Journal honored Ozette CEO Ali Ansary on its list of the top 40 dynamic leaders under the age of 40 in the business community who are moving the needle for the PNW startup ecosystem by making an impact in business, philanthropy, and their communities. Ali’s leadership and conviction inspire our team every day to remember Ozette’s ultimate goal: To accelerate scientific discovery for new therapies that improve patients’ quality of life and cure disease.
Click through to PSBJ to read the full profile on Ali and Ozette, available with subscription.
As the premiere cytometry conference convenes in Montréal this May at CYTO 2023, join our team for the first public look at how our single-cell infrastructure platform unlocks the full potential of modern, high-dimensional flow cytometry.
Four scientific presentations will highlight the speed, resolution, and scale of Ozette’s core technologies. You can also meet the team members who developed Ozette’s assay-to-insights solutions on the exhibition floor (booth 539) and hear directly from translational science and computational domain experts Cherie Green and Greg Finak in a commercial tutorial for a peek behind the scenes of our new product offerings.
We are thrilled to welcome Ashley Wilson, PhD, who will lend her deep expertise in immunology, cell therapy, and clinical trials to help drive the next generation of high-dimensional single cell immune assays. She and her team will employ Ozette’s state-of-the-art immunology lab to accelerate and power an “assay to analysis” solution that allows Ozette and partners to realize the full potential of every immune dataset.
“I’m excited to build value through collaboration and drive rapid new breakthroughs for our industry partners, harnessing Ozette’s exciting advancements that allow us to see single-cell immune data at a new remarkable resolution and breadth within days or weeks, not months or years.” said Dr. Wilson.
We are honored to welcome world-renowned physician scientist and immuno-oncology pioneer Dr. Stanley Riddell to our Board of Directors. Dr. Riddell was the founding scientific director of the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Center and leads an innovative translational research program that has led to the first adoption of immunotherapies. He co-founded transformative biopharmaceutical companies including Juno Therapeutics (acquired by Celgene in 2018) and Lyell Immunopharma (IPO 2021).
“Ozette eliminates bottlenecks in immunotherapy research and development, accelerating the newest generation of therapies that harness the power of the immune system to treat disease. The computational and machine learning methods being developed at Ozette unlock insights across oncology, autoimmune disorders, and infectious diseases that cannot be otherwise surfaced using traditional approaches,” said Dr. Riddell. “I’m thrilled to join the Ozette team on their board as they pioneer and transform a space that is ripe for innovations.”
Business Insider features Ozette as one of the 21 most promising healthtech startups, along with Solv, Truepill and WELL Health, as ranked by VCs. Haomiao Huang at Kleiner Perkins nominated Ozette, noting that, “Ozette’s AI-driven solution has been succeeding in turning these high-dimensional problems in immune profiling into solvable and usable building blocks for drug development and scientific research.” Click through to Business Insider to read the full list, available with subscription.
We’re proud to announce Ozette co-founder and Scientific Advisor Dr. Raphael Gotardo’s role as principal investigator for The Chan Zuckerberg Initiative project to decode single-cell CITE-seq data, co-led by associate professor at the Fred Hutchinson Cancer Center Dr. Evan Newell.
Hear Ozette co-founder and CTO Greg Finak discuss how we leverage machine learning in next generation high-resolution immune profiling.
Fred Hutch spin out Ozette, raises 6M in seed funding to develop its AI powered immune monitoring platform in a round led by Madrona Venture Group. Ozette’s raise will fund team growth and technology development.
An incomplete list of Ozette news and featured publications.
Please contact us at contact@ozette.com